Skip to main content
. 2004 Apr 2;557(Pt 2):635–643. doi: 10.1113/jphysiol.2004.062984

Figure 3. Urinary NOx and PGE2 changes.

Figure 3

A, urinary NOx changes in AIA. The vehicle-treated AIA group (•) was significantly different from SC-236 (▴), indomethacin (▪) and non-inflamed control (○) groups (P < 0.01, P < 0.005 and P < 0.01, respectively, two-way ANOVA). Both SC-236 and indomethacin reduced NOx levels to control levels (no significant difference from non-inflamed controls; two-way ANOVA). The non-inflamed controls did not significantly change with time (one-way ANOVA). Data presented as mean ± s.e.m. (n = 5–6). B, urinary PGE2 changes in AIA. There was an acute increase in PGE2 levels in the vehicle-treated AIA group (•) after day 1 (just failing to reach significance with time compared to SC-236 (▴), indomethacin (▪) and non-inflamed control (○) groups). The response over the first 3 days was significantly different from non-inflamed controls (P < 0.05, two-way ANOVA). The non-inflamed control group did not significantly change with time (one-way ANOVA) and did not differ significantly from either indomethacin or SC-236 (two-way ANOVA). Data presented as mean ±s.e.m. (n = 4).